Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027

Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027 European Patent Office Notifies Company of Intent to Grant Patent LONDON, July 23 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, today announces new intellectual property cover for its lead product, Atu027. The European Patent Office announced on July 17, 2008 that it intends to grant a European patent covering Silence's lead internal product candidate. This patent will give Silence broad exclusivity not only for Atu027, but for any siRNA targeting protein kinase N beta. The notice is based on European patent application EP 03 790 894.4. The claims deemed allowable by the European Patent Office are directed to various aspects of the use of protein kinase N beta, the gene... [read full story]